Vanderbilt Center for Antibody Therapeutics (VCAT)

New target to stop Ebola

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.

Alphavirus “Achilles heel”

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.

a brown rat sitting on a wood surface

Study seeking to isolate antibodies against rabies virus

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.

Research lab honored by World Vaccine Congress

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

Computer illustration of a plasma cell (B-cell, left) secreting antibodies (white) against influenza viruses (right). Antibodies bind to specific antigens, for instance viral proteins, marking them for destruction by phagocyte immune cells.

Flu Fighter: Dr. James Crowe is leading a global effort to take the guesswork out of the flu shot

From Vanderbilt Magazine: James Crowe, director of the Vanderbilt Vaccine Center, hopes to create a universal flu vaccine–permanently eliminating the problem of ineffective or under-effective annual flu shots.

1 6 7 8 9 10 14